Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same
View Patent ↗Host cells that are engineered to produce benzylisoquinoline alkaloid (BIAs) precursors, such as norcoclaurine (NC) and norlaudanosoline (NL), are provided. The host cells may have one or more engineered modifications selected from: a feedback inhibition alleviating mutation in a enzyme gene; a transcriptional modulation modification of a biosynthetic enzyme gene; an inactivating mutation in an enzyme; and a heterologous coding sequence. Also provided are methods of producing a BIA of interest or a precursor thereof using the host cells and compositions, e.g., kits, systems etc., that find use in methods of the invention.
1. A method of preparing a metabolite that is a precursor benzylisoquinoline alkaloid product, the method comprising:
culturing an engineered non-plant cell with a feed stock, said engineered non-plant cell comprising three coding sequence modifications, wherein the three coding sequence modifications are modifications to coding sequences that encode a first, second, and third enzyme, respectively, that are involved in a metabolic pathway that produces the precursor benzylisoquinoline alkaloid product,
wherein the precursor benzylisoquinoline alkaloid product is selected from the group consisting of a tyrosine, 4-hydroxyphenylacetaldehyde, 4-hydroxyphenylpyruvic acid, L-3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetaldehyde, dopamine, norcoclaurine, and norlaudanosoline, and
wherein the first enzyme involved in the metabolic pathway that produces the precursor benzylisoquinoline alkaloid product is selected from the group consisting of Transketolase (TKL1), Glucose-6-phosphate dehydrogenase (ZWF1), Pentafunctional AROM protein (ARO1), Bifunctional chorismate synthase (ARO2), 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (ARO3), 3-deoxy-d-arabinose-heptulosonate-7-phosphate synthase (ARO4), Chorismate mutase (ARO7), tyrosinase (TYR1), and tyrosinase (TYR),
wherein the second enzyme involved in the metabolic pathway that produces the precursor benzylisoquinoline alkaloid product is selected from the group consisting of TKL1, ZWF1, ARO1, ARO2, ARO3, ARO4, ARO7, TYR1, NCS, TYR, Aromatic aminotransferase (ARO9), Phenylpyruvate decarboxylase (ARO10), TyrH, DODC, and MAO, and
wherein the third enzyme involved in the metabolic pathway that produces the precursor benzylisoquinoline alkaloid product is selected from the group consisting of TKL1, ZWF1, ARO1, ARO2, ARO3, ARO4, ARO7, TYR1, and TYR.
2. The method of claim 1 , wherein each of the three coding sequence modifications is selected from the group consisting of a feedback inhibition alleviating mutation, a transcriptional modulation, an inactivating mutation, and an addition of a heterologous coding sequence.
3. The method of claim 1 , wherein the precursor benzylisoquinoline alkaloid product is selected from the group consisting of tyrosine, 4-hydroxyphenylacetaldehyde, 4-hydroxyphenylpyruvic acid, L-3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetaldehyde, dopamine, and norlaudanosoline.
4. The method of claim 1 , wherein the precursor benzylisoquinoline alkaloid product is selected from the group consisting of tyrosine, 4-hydroxyphenylacetaldehyde, 4-hydroxyphenylpyruvic acid, L-3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetaldehyde, dopamine, and norcoclaurine.
5. The method of claim 1 , wherein the engineered non-plant cell is selected from the group consisting of microbial cells, insect cells, mammalian cells, bacterial cells, and yeast cells.
6. The method of claim 1 , wherein the engineered non-plant cell is cultured under in vitro conditions.
7. The method of claim 1 , wherein the engineered non-plant cell is cultured under in vivo conditions.
8. The method of claim 2 , wherein the engineered non-plant cell comprises at least one inactivating mutation that increases production of the precursor benzylisoquinoline alkaloid product.
9. The method of claim 8 , wherein the inactivating mutation affects a coding sequence of an enzyme that is native to the non-plant cell.
10. The method of claim 8 , wherein the inactivating mutation involves inactivation of a ZWF1 enzyme.
11. The method of claim 8 , wherein the inactivating mutation involves inactivation of an enzyme selected from alcohol dehydrogenase 2 (ADH2), alcohol dehydrogenase 3 (ADH3), alcohol dehydrogenase 4 (ADH4), alcohol dehydrogenase 5 (ADH5), alcohol dehydrogenase 6 (ADH6), alcohol dehydrogenase 7 (ADH7), and bifunctional alcohol dehydrogenase (SFA1).
12. The method of claim 8 , wherein the inactivating mutation involves inactivation of an enzyme selected from Aldehyde oxidase 2 (ALD2), Aldehyde oxidase 3 (ALD3), Aldehyde oxidase 4 (ALD4), Aldehyde oxidase 5 (ALD5), and Aldehyde oxidase 6 (ALD6).
13. The method of claim 2 , wherein the engineered non-plant cell comprises at least one feedback inhibition alleviating mutation modification.
14. The method of claim 13 , wherein the at least one feedback inhibition alleviating mutation modification affects a coding sequence of an enzyme that is native to the non-plant cell.
15. The method of claim 13 , wherein the at least one feedback inhibition alleviating mutation modification affects an enzyme selected from ARO4 and ARO7.
16. The method of claim 15 , wherein the at least one feedback inhibition alleviating mutation of the ARO4 gene comprises substituting lysine residue at position 229 with a leucine.
17. The method of claim 15 , wherein the at least one feedback inhibition alleviating mutation of the ARO4 gene comprises substituting glutamine residue at position 166 with a lysine.
18. The method of claim 15 , wherein the at least one feedback inhibition alleviating mutation of the ARO7 gene comprises substituting the threonine residue at position 226 with an isoleucine.
19. The method of claim 2 , wherein the engineered non-plant cell comprises at least one transcription modulation modification.
20. The method of claim 19 , wherein the at least one transcription modulation modification affects a coding sequence of an enzyme that is native to the non-plant cell.
21. The method of claim 19 , wherein the transcription modulation modification comprises substituting a native promoter of an enzyme selected from the group consisting of ARO1, ARO3, ARO4, ARO7, TYR1, ARO9, ARO10, and TKL for a promoter selected from the group consisting of a GAPDH promoter, an ADHI promoter, a Gal1-10 promoter, a Gal1 promoter, a GalL promoter, a GalS promoter, a GPD promoter, an ADH promoter, a TEF promoter, a CYC1 promoter, and an MRP7 promoter.
22. The method of claim 2 , wherein the engineered non-plant cell comprises at least one addition of a heterologous coding sequence modification, wherein the heterologous coding sequence encodes an enzyme selected from the group consisting of TYR, TyrH, GTP Cyclohydrolase (FOL2), 6-pyruvoyl tetrahydro-biopterin synthase (PTPS), Sepiapterin reductase (SepR), 4a-hydroxytetrahydrobiopterin (PCD), Quinoid dihydropteridine reductase (QDHPR), DODC, Tyrosine/DOPA decarboxylase (TYDC), MAO, NCS, Norcoclaurine 6-O-methyltransferase (6OMT), Coclaurine-N-Methyltransferase (CNMT), and 4′-O-methyltransferase (4′OMT).
23. The method of claim 1 , wherein the engineered non-plant cell produces norcoclaurine.
24. The method of claim 1 , wherein the engineered non-plant cell produces norlaudanosoline.
25. The method of claim 1 , wherein the engineered non-plant cell produces reticuline.